ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Huggins, 1941, Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, 293 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1036, 10.1056/NEJM199810083391504 Heidenreich, 2008, EAU guidelines on prostate cancer, Eur Urol, 53, 68, 10.1016/j.eururo.2007.09.002 Chang, 1988, Molecular cloning of human and rat complementary DNA encoding androgen receptors, Science, 240, 324, 10.1126/science.3353726 Chen, 2004, Molecular determinants of resistance to antiandrogen therapy, Nat Med, 10, 33, 10.1038/nm972 Dehm, 2008, Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance, Cancer Res, 68, 5469, 10.1158/0008-5472.CAN-08-0594 Hu, 2009, Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer, Cancer Res, 69, 16, 10.1158/0008-5472.CAN-08-2764 Guo, 2009, A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth, Cancer Res, 69, 2305, 10.1158/0008-5472.CAN-08-3795 Sun, 2010, Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, J Clin Invest, 120, 2715, 10.1172/JCI41824 Heinlein, 2004, Androgen receptor in prostate cancer, Endocr Rev, 25, 276, 10.1210/er.2002-0032 Watson, 2010, Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor, Proc Natl Acad Sci USA, 107, 16759, 10.1073/pnas.1012443107 Niu, 2008, Androgen receptor is a tumor suppressor and proliferator in prostate cancer, Proc Natl Acad Sci USA, 105, 12182, 10.1073/pnas.0804700105 Mir, 2010, Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study, BJU Int, 108, 24, 10.1111/j.1464-410X.2010.09834.x Miyamoto, 2007, Promotion of bladder cancer development and progression by androgen receptor signals, J Natl Cancer Inst, 99, 558, 10.1093/jnci/djk113 Yang, 2007, ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor, Nat Med, 13, 348, 10.1038/nm1547 Wu, 2010, Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription, Sci Transl Med, 2, 32ra35, 10.1126/scitranslmed.3001143 Ohtsu, 2002, Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents, J Med Chem, 45, 5037, 10.1021/jm020200g Marks, 2008, Prostate tissue androgens: history and current clinical relevance, Urology, 72, 247, 10.1016/j.urology.2008.03.033 Zhang, 2011, Androgen receptor variants occur frequently in castration resistant prostate cancer metastases, PLoS One, 6, e27970, 10.1371/journal.pone.0027970 Pretlow, 1993, Xenografts of primary human prostatic carcinoma, J Natl Cancer Inst, 85, 394, 10.1093/jnci/85.5.394 Wainstein, 1994, CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma, Cancer Res, 54, 6049 Nagabhushan, 1996, CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar, Cancer Res, 56, 3042 Sramkoski, 1999, A new human prostate carcinoma cell line, 22Rv1, In Vitro Cell Dev Biol Anim, 35, 403, 10.1007/s11626-999-0115-4 Horoszewicz, 1980, The LNCaP cell line—a new model for studies on human prostatic carcinoma, Prog Clin Biol Res, 37, 115 van Bokhoven, 2003, Molecular characterization of human prostate carcinoma cell lines, Prostate, 57, 205, 10.1002/pros.10290 Wu, 1994, Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells, Int J Cancer, 57, 406, 10.1002/ijc.2910570319 Lin, 1998, Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines, J Biol Chem, 273, 5939, 10.1074/jbc.273.10.5939 Tepper, 2002, Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line, Cancer Res, 62, 6606 Li, 2011, Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression, Cancer Res, 71, 2108, 10.1158/0008-5472.CAN-10-1998 Chen, 2010, ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines, J Biol Chem, 285, 2368, 10.1074/jbc.M109.049379 Gregory, 2001, Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen, Cancer Res, 61, 2892